Progress in cancer chemotherapy with special stress on molecular-targeted therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacogenomics

Background:

• Significant advancements in molecular biology have driven the development of numerous molecular-targeted drugs.
• Approved therapies include antibodies and small molecule tyrosine kinase inhibitors, transforming standard cancer care.

Purpose of the Study:

• To highlight the impact of molecular-targeted therapy on cancer treatment paradigms.
• To emphasize the role of pharmacogenomics in individualized cancer care.
• To discuss the importance of biomarker testing in guiding targeted treatments.

Main Methods:

• Review of clinical applications of molecular-targeted drugs.
• Analysis of survival data and cure rates associated with targeted therapies.
• Identification of key prognostic and predictive biomarkers in various cancers.

Main Results:

• Molecular-targeted therapy has led to significantly improved progression-free and overall survival rates.
• Cure rates have increased, particularly in surgically resected patients.
• Mandatory biomarker testing (e.g., HER2, Kras, EGFR) is now standard for specific cancers.

Conclusions:

• Molecular-targeted therapies have fundamentally changed cancer treatment, offering personalized approaches.
• Further development of targeted agents and validated biomarkers holds promise for increasing cure rates, even in advanced cancers.